CD274 and non-small cell lung carcinoma: Several anti- PD-1/PD-L1 antibodies (Nivolumab, Pembrolizumab, and Atezolizumab) have shown significant advantages in certain malignancies such as melanoma, non-small-cell lung cancer (NSCLC) and urothelial carcinoma, and have been approved by the Food and Drug Administration [28–30].